Clinical Trials

1,524 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

400 enrolled

Colonic Neoplasms

NCT01613482 2026-03-16

TSARINE

Phase 3 Terminated

13 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT03264547 2025-09-29

EMERALD

446 enrolled

Breast Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

300 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Breast Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

700 enrolled

Colonic Neoplasms

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

2,306 enrolled

HER2-positive Breast Cancer

NCT07062263 2025-07-14

TAB-2

220 enrolled

Biliary Tract Neoplasms

NCT02625441 2025-02-11

BOLD-1

516 enrolled

Breast Neoplasms

NCT02578368 2024-11-12

FLOT5

183 enrolled

Stomach Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT03595592 2024-03-06

APTneo

650 enrolled

Invasive Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

312 enrolled

HER2-positive Metastatic Breast Cancer

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

372 enrolled

Breast Neoplasms

NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

1,406 enrolled

Phase 3 Not yet recruiting

HER2 Positive Early Breast Cancer

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

876 enrolled

Breast Neoplasms

NCT00004935 2023-04-18

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Phase 3 Terminated

175 enrolled

Breast Neoplasms

NCT01875367 2023-04-05

ChangHER-SC

166 enrolled 24 charts

Breast Neoplasms

NCT03705429 2022-08-19

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

51 enrolled

Breast Neoplasms

NCT05188313 2022-06-24

TRAP-2

376 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

120 enrolled

Phase 3 Not yet recruiting

HER2+ Breast Cancer

NCT05388500 2022-05-27

PHARE-C

800 enrolled

HER2-positive Breast Cancer

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

240 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT04973319 2021-07-22

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

450 enrolled

Breast Neoplasms

NCT00047255 2020-08-03

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

263 enrolled

Breast Neoplasms

NCT01950182 2020-07-15

SYSUCC-002

392 enrolled

Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

493 enrolled

Breast Neoplasms

NCT01104935 2019-10-21

RESPECT

275 enrolled

Breast Neoplasms

NCT01104571 2018-09-17

EPHOS-B

257 enrolled

Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

961 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT00053339 2016-07-12

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Phase 3 Withdrawn

Breast Neoplasms

NCT00567554 2016-02-10

GeparQuinto

2,600 enrolled

Breast Neoplasms

NCT00593697 2015-03-06

SOLD

2,168 enrolled

Breast Neoplasms

NCT00615602 2015-03-04

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

489 enrolled

Breast Neoplasms

NCT00054587 2013-07-19

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

3,010 enrolled

Breast Neoplasms

NCT00440622 2013-02-13

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase 3 Terminated

90 enrolled

Breast Neoplasms, Neoplasms

NCT00038402 2012-07-20

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

74 enrolled

Breast Neoplasms

NCT00148876 2011-02-23

TBP Study With Capecitabine Plus Minus Trastuzumab

482 enrolled

Breast Neoplasms

NCT00146549 2009-11-02

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT00430001 2008-05-09

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

300 enrolled

Breast Neoplasms

NCT00637325 2008-03-17

TOP